A Phase III Randomized Double-blind, Placebo-controlled Trial of ARQ 197 in Subjects With c-MET Diagnostic-high Inoperable Hepatocellular Carcinoma (HCC) Treated With One Prior Sorafenib Therapy
Phase of Trial: Phase III
Latest Information Update: 27 Mar 2017
At a glance
- Drugs Tivantinib (Primary)
- Indications Liver cancer
- Focus Therapeutic Use
- Acronyms JET-HCC
- Sponsors Kyowa Hakko Kirin
- 27 Mar 2017 Status changed from recruiting to completed according to an ArQule media release.
- 27 Mar 2017 According to an ArQule media release, details of the study results will be presented in an upcoming scientific forum.
- 27 Mar 2017 Primary endpoint (Progression-free survival) has not been met, according to an ArQule media release.